The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
EHA 2025 | Emerging options for the management of patients with DLBCL who relapse following CAR-T
In this video, Matthew Ku, St Vincent’s Hospital, University of Melbourne, Melbourne, Australia, comments on the management of patients with diffuse large B-cell lymphoma (DLBCL) who progress after CAR T-cell therapy, highlighting the need for novel treatments to improve outcomes. Prof. Ku suggests that potential therapeutic options include bispecific T-cell engagers (glofitamab, mosunetuzumab, and epcoritamab), novel CAR-T approaches (bispecific or armored CAR T-cells), and antibody-drug conjugates. This interview took place at the 30th Congress of the European Hematology Association (EHA) in Milan, Italy.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
Yeah, it’s a very important question and it’s an area of unmet medical need. We know that, you know, a lot of patients once they’ve progressed after CAR-T, their prognosis is poor. So far, really the evidence is more around bispecific T-cell engagers. So we know that there’s evidence behind glofitamab, mosunetuzumab and epcoritamab in terms of salvage patients that have failed standard of care CD19 CAR-T’s but despite that the efficacy is still not where we like it to be, it’s fairly suboptimal still, so we’d like to improve that...
Yeah, it’s a very important question and it’s an area of unmet medical need. We know that, you know, a lot of patients once they’ve progressed after CAR-T, their prognosis is poor. So far, really the evidence is more around bispecific T-cell engagers. So we know that there’s evidence behind glofitamab, mosunetuzumab and epcoritamab in terms of salvage patients that have failed standard of care CD19 CAR-T’s but despite that the efficacy is still not where we like it to be, it’s fairly suboptimal still, so we’d like to improve that. So you know the other options apart from bispecifics would be something like this a bispecific CAR-T, so a different type of CAR-T may be targeting a different antigen rather than the CD19. So different types of CAR-Ts whether you know you have armored CAR-Ts or bispecific CAR-Ts or even allogeneic CAR-Ts as a potential salvage agent. The other option would be something like an antibody-drug conjugate. You know that’s also something that is being looked at so bispecifics, novel CAR-Ts, and antibody-drug conjugates could be you know the next thing to look at in terms of salvaging the CAR-T failed patients.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
Disclosures
Consultancy: Roche, Abbvie; Research Funding: Beigene, Roche.
